Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Type of Subject: Outpatient~* Age: ≥12 years of age~* Gender: Eligible Female (females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control)~* Asthma Diagnosis: As defined by NIH~* Severity of Disease: FEV1 50-85% predicted AND in current and former smokers a post salbutamol/albuterol ratio \>0.70~* Reversibility: ≥12% and ≥200mL in FEV1 within 30 ±15 minutes following salbutamol/albuterol~* Current anti-asthma therapy: Using short-acting beta-agonist (SABA) for ≥3 months~* Tobacco use: Non-smoker /former smoker with ≤10 pack years or current smoker with ≤10 pack years~* QTC: QTc(F)\<450msec or QTc(F)\<480 for subjects with Bundle Branch Block~* Liver function: Normal liver function~* Informed Consent~Exclusion Criteria:~* History of Life-threatening asthma: Within previous 5 years~* Asthma Exacerbation: Requiring OCS within 3 months or hospitalisation within 6 months~* Respiratory Infection: Not resolved within the 4 weeks before V1 AND led to a change in asthma management OR treatment with antibiotics OR is expected to affect the subject's asthma status or ability to participate~* Corticosteroid Use: ICS used within 6 weeks or OCS/depot corticosteroids within 12 weeks~* OATP1B1 substrates: OATP1B1 substrates (e.g. statins, rifampicin, bromosulphophthalein, benzylpenicillin, methotrexate) within 4 weeks~* Immunosuppressive medications: Either using or required during the study~* Liver disease: Current or chronic history~* Concurrent disease/abnormalities: Clinically significant uncontrolled disease~* Investigational medications: Participation in a study or used investigational drug within 30 days~* Drug allergy: β-agonists, corticosteroids, constituents of inhalers~* Milk Protein Allergy: History of severe milk protein allergy~* Compliance: Factors likely to impair compliance either with regards to study medication, procedures or attendance~* Unable or unwilling to follow instructions: Procedures, dosing directions, e-diaries or pMDIs~* History of alcohol or drug abuse: Likely to interfere with the study~* Affiliation with Investigator's Site: Relative or employee

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK2190915 10mg and placebo (Type: EXPERIMENTAL): GSK2190915 10mg (1 x 10mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
- GSK2190915 30mg and placebo (Type: EXPERIMENTAL): GSK2190915 30mg (1 x 30mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
- GSK2190915 100mg QD and placebo (Type: EXPERIMENTAL): GSK2190915 100mg (1 x 100mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
- GSK2190915 300mg QD and placebo (Type: EXPERIMENTAL): GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
- Fluticasone propionate 100mcg and placebo (Type: ACTIVE_COMPARATOR): Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS and two placebo tablets in the morning and one placebo capsule in the evening
- Montelukast 10mg and placebo (Type: ACTIVE_COMPARATOR): Montelukast 10mg (1 x 10mg capsule) once daily in the evening and two placebo tablets in the morning and inhaled placebo twice daily via ACCUHALER/DISKUS
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Two GSK2190915 placebo tablets once daily in the morning, montelukast placebo capsule once daily in the evening and fluticasone propionate placebo twice daily via ACCUHALER/DISKUS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete